About CLINUVEL

Announcements

CLINUVEL's company releases, including archives.

Friday, 24 February 2017 19:44

Appendix 4D and Half Year Report

Thursday, 16 February 2017 00:41

CLINUVEL Newsletter - February 2017

Tuesday, 31 January 2017 19:34

Appendix 4C - Quarterly report

Friday, 23 December 2016 20:08

Appendix 3Y

Tuesday, 20 December 2016 22:03

CLINUVEL Newsletter - December 2016

Tuesday, 13 December 2016 02:25

Appendix 3Y

Monday, 28 November 2016 15:01

Results of Meeting

Sunday, 27 November 2016 13:19

Managing Director's AGM Presentation

Melbourne, Australia and New York, US, 9 November 2016 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that it met on 7 November with the US Food and Drug Administration’s (FDA’s) Division of Dermatology and Dental Products (DDDP) to discuss the content and format of a new drug application (NDA) submission as part of the US regulatory pathway for CLINUVEL’s medicinal product SCENESSE® (afamelanotide 16mg). The pharmaceutical product has been developed for the treatment of erythropoietic protoporphyria (EPP)1, a rare genetic enzymatic disorder causing lifelong absolute light intolerance. The pre-NDA meeting allowed both parties to discuss…
Page 1 of 46

Latest Company Announcements

31 January 2017

Appendix 4C - Quarterly report

Quarterly report

Read More
23 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
20 December 2016

CLINUVEL Newsletter - December 2016

At the end of a calendar year we look back on plenty of activities and a solid financial performance by the CLINUVEL Group.

Read More
12 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
28 November 2016

Results of Meeting

AGM results

Read More
27 November 2016

Chair's Address to the Annual General Meeting

I would like to commence my address by saying it is always a pleasure to welcome familiar and a few new faces to the CLINUVEL Annual General meeting.

Read More

Quick Links